In-Licensing and Supply - Additional Information (Detail) - USD ($) |
1 Months Ended | 3 Months Ended | ||||||
|---|---|---|---|---|---|---|---|---|
Dec. 31, 2018 |
Sep. 30, 2025 |
Mar. 31, 2026 |
Dec. 31, 2025 |
Sep. 30, 2024 |
Aug. 31, 2024 |
|||
| In Licensing and Supply [Line Items] | ||||||||
| Capitalized milestone payments | [1] | $ 15,360,000 | $ 15,360,000 | |||||
| Intangible assets, net | 14,176,000 | $ 14,452,000 | ||||||
| Aegis Therapeutics Agreement | ||||||||
| In Licensing and Supply [Line Items] | ||||||||
| Upfront License Fees | $ 50,000,000 | |||||||
| Aggregate milestone payments upon achievement of certain sales milestones | 20,000,000 | |||||||
| Milestone payment due | $ 9,000,000 | |||||||
| Milestone payment recognized | $ 2,000,000 | |||||||
| Capitalized milestone payments | $ 2,500,000 | |||||||
| Notice Period Description | The Company may terminate the Aegis Agreement with 30 days written notice or either party may terminate the Aegis Agreement for certain breaches of the Aegis Agreement. Unless terminated earlier by either or both parties, the term of the Aegis Agreement will continue until the final expiration of all royalty obligations under the Aegis Agreement. | |||||||
| Legal Patent Fees | $ 0.1 | |||||||
| Aegis Therapeutics Agreement | First Commercial Sale Of Neffy | ||||||||
| In Licensing and Supply [Line Items] | ||||||||
| Capitalized milestone payments | $ 5,000,000 | |||||||
| Aegis Therapeutics Agreement | Research and Development Expense [Member] | ||||||||
| In Licensing and Supply [Line Items] | ||||||||
| Regulatory milestone | $ 1,500,000 | |||||||
| Renaissance Agreement | ||||||||
| In Licensing and Supply [Line Items] | ||||||||
| Contract Termination Claims, Description | Either party may elect not to renew the U.S. Renewal Term and/or the EU Renewal Term by providing the requisite prior notice to the other party, with the initial terms automatically renewing for successive two-year terms, unless either party gives notice pursuant to the Renaissance Agreement. Either party may terminate the Renaissance Agreement (1) for uncured material breach of the other party, (2) upon notice for insolvency-related events of the other party that are not discharged within a defined time period, (3) on a product-by-product basis if the manufacture, distribution or sale would materially contravene any applicable law, (4) by providing the requisite notice if (a) the authorization and approval to distribute or sell Renaissance Product in the U.S. is not granted on or before a specified date, (b) the authorization and approval representing more than a certain number of units of Renaissance Product sold in the U.S. during the last calendar year is withdrawn by the FDA, or (c) the Company decided in its sole discretion to cease commercializing the Renaissance Product in the U.S., (5) in the case of a force majeure event that continues for six months or more, or (6) a violation by the other party of trade control or anti-corruption laws. | |||||||
| ||||||||